<SEC-DOCUMENT>0001376339-17-000149.txt : 20171130
<SEC-HEADER>0001376339-17-000149.hdr.sgml : 20171130
<ACCEPTANCE-DATETIME>20171130102706
ACCESSION NUMBER:		0001376339-17-000149
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171130
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171130
DATE AS OF CHANGE:		20171130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				900300868
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		171230186

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		678-384-6720

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a113020178-kdocumentrevenu.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s64404fbc90814d1ab0d9af7c10d9c180"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (date of earliest event reported): November 30, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">MIMEDX GROUP, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:4%;"></td><td style="width:31%;"></td><td style="width:4%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Florida</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35887</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26-2792552</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1775 West Oak Commons Ct, NE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marietta, GA</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">30062</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(770) 651-9100</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49px;"></td><td style="width:486px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:552px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49px;"></td><td style="width:502px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:664px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49px;"></td><td style="width:614px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:653px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49px;"></td><td style="width:604px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation FD Disclosure</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 30, 2017, MiMedx Group, Inc. issued a press release announcing its expectations for revenues for the period ended December 31, 2017. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;</font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a113020178-kexhibitpressre.htm"><font style="font-family:inherit;font-size:10pt;">MiMedx Group, Inc. Press Release dated November 30, 2017</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:7%;"></td><td style="width:51%;"></td><td style="width:4%;"></td><td style="width:29%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 30, 2017</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/: Michael J. Senken</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael J. Senken, Chief Financial Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a113020178-kexhibitpressre.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s39de4cd2a71e4252af0b1e8a631fcc1b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;"><img src="logo.jpg" alt="logo.jpg" style="color:#1e60ad;font-family:Arial;font-size:11pt;font-style:italic;font-weight:bold;height:82px;width:242px;"></div><div style="line-height:174%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">PRESS RELEASE Contact:  Michael Senken</font></div><div style="line-height:174%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Phone: (770) 651-9100</font></div><div style="line-height:174%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">MiMEdx Announces Expectation To Exceed Top End of FOURTH QUARTER Revenue Guidance Of $88 Million </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Marietta, Georgia</font><font style="font-family:Arial;font-size:11pt;">, November 30, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its preliminary expectation for fourth quarter of 2017 revenue to exceed the $88 million high end of its fourth quarter revenue guidance range. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Parker H. &#8220;Pete&#8221; Petit, Chairman and CEO, commented, &#8220;October and November have been very strong revenue months for the Company, and we expect our revenue performance in December to be equally strong.  With two-thirds of the fourth quarter completed, and as we enter December, our current revenue pace gives us confidence that we are in a position to announce that we expect to exceed $88 million in revenue for the fourth quarter of 2017 and surpass our previously published guidance for the fourth quarter and full year 2017. If we execute as expected, this will be the fourth straight quarter of exceeding the upper end of our guidance.&#8221;  </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Bill Taylor, President and COO, said, &#8220;Our sales leadership team has never been stronger, and we are extremely pleased with the momentum they continue to build.  Each quarter, we are improving efficiencies in our sales organization and increasing effectiveness in pursuing and capturing market opportunities.&#8221; </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Petit added, &#8220;We look forward to reporting our 2017 fourth quarter and full year revenue in January and our 2017 financial results in late February. We are holding a meeting of our Board of Directors during the week of December 11</font><font style="font-family:Arial;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th </sup></font><font style="font-family:Arial;font-size:11pt;">to finalize our 2018 budget, and we are also looking forward to announcing our 2018 guidance later in that week.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About MiMedx</font><font style="font-family:Arial;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">MiMedx&#174; is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. &#8220;</font><font style="font-family:Arial;font-size:11pt;font-style:italic;font-weight:bold;">Innovations in Regenerative Medicine"</font><font style="font-family:Arial;font-size:11pt;">&#32;is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION&#174; Process among other processes, to produce safe and effective allografts.   MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit </font><font style="font-family:Arial;font-size:10pt;color:#00497f;text-decoration:underline;">www.mimedx.com</font><font style="font-family:Arial;font-size:11pt;color:#00497f;">. </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Important Cautionary Statement</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This press release includes forward-looking statements, including statements regarding its revenue expectations for the 2017 fourth quarter and full year and its expectations regarding the timing of additional guidance. These statements also may be identified by words such as &#8220;believe,&#8221; &#8220;except,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;will&#8221; and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#1e60ad;font-style:italic;font-weight:bold;">Innovations In Regenerative Biomaterials</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">MiMedx Group, Inc.  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|  </font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">1775 West Oak Commons Ct NE  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;Marietta, GA 30062  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;770.651.9100  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;Fax 770.590.3550  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;www.mimedx.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">undue reliance on such statements.  Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that the Company&#8217;s revenue for the 2017 fourth quarter and full year may not materialize as expected; sales momentum may slow at the end of the year; and the Company may be unable to meet expected dates for future guidance. For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission.  Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#333333;font-weight:bold;">Investor Contact:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#333333;">COCKRELL GROUP</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#333333;">Rich Cockrell</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#333333;">877-889-1972</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#00497f;">investorrelations@thecockrellgroup.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#00497f;text-decoration:underline;">cockrellgroup.com</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#1e60ad;font-style:italic;font-weight:bold;">Innovations In Regenerative Biomaterials</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">MiMedx Group, Inc.  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|  </font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">1775 West Oak Commons Ct NE  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;Marietta, GA 30062  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;770.651.9100  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;Fax 770.590.3550  </font><font style="font-family:inherit;font-size:8pt;color:#005a9b;">|</font><font style="font-family:inherit;font-size:8pt;color:#5a5a5a;">&#32;&#32;www.mimedx.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>MIMEDX LOGO
<TEXT>
begin 644 logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@!&8(,DX% %1KU1P@9S[#_ #_*@"%KFY/W
M(L?7_(H A:6^[(!^7_Q5,"$W5\G6//\ P$G^1H B_MN6(XEBQ^:_S!H$68M=
M@;APR?49'YC/\J!FI#<13C,3*WT/].HI 34 % !0 4 % !0 4 % !0 4 % !
M0 4 % "'/;B@!GDKG)^8^_\ G% $@&.!Q0 4 % !0 A4,,$9'H: *$VE6TW5
M I]5^7^7'Z4 8L^@RQ'?;/DCH#\K?@1Q_*F(ABU>ZL6\NY4L!V;AOP;HWZ_6
M@9TEI?PW@_=-\PZJ>&'X?U&12 N4 % !0 4 % !0!AZUKB:+Y>]&D\W=C:0,
M;<=<^N:ZJ-%UKV:5K?B<E:NJ%KIN]]O*W^9F67C""[G2 QO'YAVAB5P">F<>
MIP/QK:>%E"+E=.VMC"&,A.2A9J[M<Z^O//2#I0!Q4OC:WC=E6)V"D@,"H! .
M,CV/45Z2P<FDW)+RUT/*>-@FTHMVZ]S9L=>BO+5[PJT:1L5P<$DX7&,>NX"N
M2K2=&7*W?2YVT:JK1<DK6=OP3_4EAUF*>"6=58&!2S*<9( )X/3G!'L:SC'F
MDHKJTOO-92Y(N?9-_=J<[_PG,'_/&3_OI:]'ZG+^9?<SS/KT?Y7]YUUA>)?P
M)<1?=<9P>H/0@^X.0:\^<'3DX/='I4YJI%3CLRW69H<_K/B*'1W6)E:1W!;"
MD#:,X&<^ISCZ5UTJ$JR<DTDM-3BK8B-!J+5VU?3H5=-\51:E<+;)$Z%\\DK@
M84MV^E:5,,Z47-R6G3U=C.GBHU9*FHM7O^39U5<!Z(4 % $4T$<Z[)%#+Z'_
M #Q]10!S%YH3PGS;,DXYVYPP_P!UN_T//N:8&2NJWRSH&F*QAU$BLBCY<C=S
MMR.,Y[^]=$'3Y7&<=;.TDWOTNKG+.-3F4J<M+J\6EM?6SM?;I^)Z"K!@&4@@
M\@CI7,=0M "%@O!(!/2@!: "@#@/'72W^LG_ +)7K8+[?R_4\7'_ &/^WOT.
M;U73_LT%K>1C"S1(&([2*.OL6'/U4FNRE/FE.F]XR=O1_P"7ZG%5I\D:=6.B
M<5?U7^:_4].T34!J5HDW\>-K^SKP?S^\/8BO$K4_93<>FZ]'_5CWJ%3VL%+K
ML_5?Y[_,H^*-1^P6;*IQ)/\ NU]0"/F/X+Q]2*UPU/GFF]HZO]/Q,L54]E3:
M6\M%^OX?F>??V=Y.E&\88::953V10^2/]YOT45Z_M+UO9K91;?J[?DOS/%]G
MRT/:O>4DEZ)/\W^1T.A2QP:-/),I=%D)*@X)XCQ@]B#S7#B(>TK1@G:\?\ST
M,+/V="4VKVEM\HEK3;NWNK"\-NCQ[8V#%V#$Y1L=   .>W>L71=&I33=[R7E
MLT;JLJ]*HTK6B_Q3.5TC3O[1MKI5&9(U1T]<@ME?^!+D?7%>G5J>SE!O9MI_
M.VOR9Y%&G[6%1+XDDU\KW7S7XV-[P5J.QGL7/#?O(_J/OC\1AOP:N7%T]%57
M31_I_D=N"J6;HOU7KU7Z_(]#=UC4NQPJ@DD]@.2?RKR$KNRW/:;25WLCRJR0
M^(]5,KC]V&WD'M&G"+^/ /U8U[LW]6H\JWM9>KW?Y_@?.P7UJOS/X;W?HME^
M2_$@\,_\A2/ZR?\ H#U>(_@OY?FB,-_'C\_R9W6K>)[;2W,(!FE'55P OLS'
MH?8 GUQ7ETL/*JN;X8]WU]$>Q5Q,*+Y?BEV73U9EGQ7=1KYLEDZQ?WLL!CUR
M8\5M]6@_=517[:?YG/\ 6YQ]YTFH]]?SL=!I.N6^KJ?*RLB\LC?> ]1C@CW'
MX@9%<E6C*C\6W1K;_@'92KPK+W=&MT]RKK'B2WTEO*P99L9**<!0>FYN<9Z@
M $XYX&*TI8>55<VT>_?T1G6Q,:#Y=Y=ET]69$/C"3 DFM76$_P :DD >O*A3
M_P!]"NAX1?#&:YNST_6_X'/'&/XI4VH]U_PUOQ.<FN_M>ILL+!HKB50I.<#=
MM&<=1CN/;%:RH+V2<E:<8O\ "^C[F$<0U6M!WA*2T];:KLSI(+JXT23R91F/
MKM[$?WD/\Q^8!YKQSW3L(;N*>/SD8;,9)/&,=<^A'?-(# ?5(KN=5BCDD8'"
MX( .#G//('OQQ[XI[ =.*0!0!P'CKI;_ %D_]DKUL%]OY?J>+C_L?]O?H:T6
MGC4M%CM_XC"I0^C@97\SP?8FN=S]E7<^G,[^CW.I4_:X>,.O*K>O3_(YCPAJ
M!L[IK23Y5FX /:1<\?B,@^X45W8J'/!5([Q_)_U^9Y^#J<DW2EM+\&OZM]Q'
MK<S:YJ:VL)RJ-Y2^G7,C_A@_@HIT4J%)SENUS/\ 1?UU9-=O$5E3CLGRK]7_
M %T1T/BV%;;38X8QA(Y(U4>P5P*Y,*W*JY/=IO\ %'=BXJ%&,8[)I+Y)F-IW
M_( NO^NA_P#:5=%3_>(>G_R1RTO]UJ?XO_D0\-?\@^^_ZYG_ -%O3Q'\2EZ_
MJA8;^%6_P_I(F\"_ZR?_ '8_YM48S:/J_P!"\#O/T7ZF3K-N^A:EYT/"[A-'
MZ8)^9?IG*X_ND>M=%*2KTN66]N5_H_U]3FK1>&K<T=%?F7^7Z>ATWB;64-@B
MP'F\ /N(^"V?<G"G_@7I7%AZ+51N7V/SZ?Y_<>AB:R]DE#[?Y=?\OO+?A'3O
ML=IY[##W'S?1!]P?CRWXCTK/%5.:?*MHZ?/K_D:82G[.',]Y:_+I_F<7X:XU
M-".WF_\ H#UZ6(_A/_MW\T>5AOXR_P"WO_264],FF-X)XXOM,V6?8<\L>2WU
M!.1[\UI445#D<N6.BOY=OF94I2]ISJ/-+5V\^_ZG;'6M7(P;'(/^]7F>QH_\
M_?R/7]M7_P"?7YF%H^GWUMJ$=QY#PQESN&/E5&SD?09XSZ"NJK.G*DX<R;MI
MW;7^9QT:=2%53Y'%7^23_P BA81KJ.K 7'(>9V8'OMW,%/MP!CTXK:;]G1]S
MI%6^=E?]3"FE4KVGUDV_Q=OT/8"H(VD#;C&,<8],>GM7SVVI]-;IT/'_ "$M
M=8$,7")<H%'H-X./PSC\*^AYG*AS/=P?Y'S/*H8A1CLIJWWGJU[:Q7496;A1
MSNZ%?<'M[]O6OG3Z<\[9C&6CC<E"<<9 < \$C]>:8CLM!@@2'S(CND;AR>"#
M_=QV _\ 'NOI@&;M( H XSQ?I]Q?"'[-&TFPONVXXSLQU(ZX->EA9QI\W.TK
MVM^)Y6,ISJ<O(KVO?\#HM'A>WLX8I 5=(U# ]00.E<=5J4Y..UW8[J*<:<8O
M1I(X?Q!H-RMZ;FQ1F$F'RF 4D!Y[C&3A@?4FO3H5H>SY*K2MIKU7]:'DXC#S
M]IST4]==.C_K7YFAX4T2:TD>ZND*.!M0-C//+-P3[ ?\"K+$UHR2A3=UN[?@
MOZ\C;"4)4VZE16>R_5_UYFIXKLYKVS6.W0R.)5.!C. K9/./45AAI1A.\W96
M?YHZ,5"52FHP5WS+\F8]CIEU%HUQ;-&RRNY*IQDC]WR.<=C^5=$ZD'7A--<J
M6K^\YJ=*<</.FXM2;T7_ (")H.F75K97D4L;(\J$(#C+'8XP.?4@45JD)5*;
MBU9/7RU0J%*<*=6,HM-K1=]&3>$--N;!YC<1M$&5 N<<X+9Z$^M+%5(S4>1I
MV;_0O!TITG+G35[6_$U/$^E-J5MF(;IH3N0#J0>&7\1@_516&'J>RG[VD7H_
MT?\ 7<Z,52]K#W5[T=5\]U^OR.&M/#M]<3117$;I$#@EB,*F2S <\9R<8[FO
M3E7IQC)P:<NW=[+^NQY$,-4E*,9IJ*_!;O\ 7YGKBJ$ 51@ 8 '8#H*\#?5G
MTB5M$>::!H]Y:Z@DTT3)&"^6.,#*L!W[DBO9KU82I.,9)O33YH\+#T:D*JE*
M+2UU^3);[0+S2KO[;IHWKN+!1RR[LY4KQN4Y(&.<>A&:4*T*L/9UM':WD[=;
M]&54P]2C/VM#57O;MY6ZKT+Q\1ZFR[%LG$O3.V0J#Z[=H_\ 0OQK+ZO23NZB
MMVNOSO\ H:_6:UK*D[][2M]UOU+>A6VJM()K^1EC .(SMRQ/ R%'R@=<9SG'
M&*SK2HI<M**OWUT-:$:]^:M)I=M-?\C&UOP]<V]R;VP!8,WF87[Z/G)('<$\
MC&<9((Q731KPE#V5732VNS7Z'+7P\X3]K1UUOINGO^9;CUS6)U\I+0B7IO*L
MJCWPV%![\MCV[5FZ-"+YG4]WM=7_  U_ U5>O)<JIVEW::7XZ?B8\.@W]O?Q
MNZ-(%EC=Y!C!R59CDD$X).3CG!KH=>G*FTFE[K27R:1R1P]6-6,FKVE%M_--
MG6:M]LO#Y,4;"$'V&\^IYX7T'XGL!X9]$6K;08D@,<OS2..6'\)[;?I_X]WX
MXH QK>TOM-G+1(7 .#C&UU_/CV[@_CD [2-]ZAB"N1G!ZCV-(!] !0 4 % !
C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
